We are live on
!
Find out more
N
Nuveen Portfolio holdings
AUM
$369B
1-Year Est. Return
31.66%
This Fund
S&P 500
This Quarter
Est. Return
+10%
1 Year Est. Return
+31.66%
3 Year Est. Return
+110.02%
5 Year Est. Return
+148.02%
10 Year Est. Return
+492.84%
AUM
$264B
AUM Growth
+$16.6B
(+6.7%)
Cap. Flow
-$3.28B
Cap. Flow
% of AUM
-1.24%
Top 10 Holdings %
Top 10 Hldgs %
18.75%
Holding
3,331
New
118
Increased
1,090
Reduced
1,840
Closed
95
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares iBoxx $ Investment Grade Corporate Bond ETF
LQD
|
+$1.03B |
| 2 |
Bristol-Myers Squibb
BMY
|
+$649M |
| 3 |
NVIDIA
NVDA
|
+$329M |
| 4 |
AT&T
T
|
+$316M |
| 5 |
Tesla
TSLA
|
+$313M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cisco
CSCO
|
+$474M |
| 2 |
CELG
Celgene Corp
CELG
|
+$421M |
| 3 |
Broadcom
AVGO
|
+$411M |
| 4 |
Netflix
NFLX
|
+$387M |
| 5 |
Apple
AAPL
|
+$372M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.51% |
| 2 | Financials | 14.64% |
| 3 | Healthcare | 13.3% |
| 4 | Consumer Discretionary | 10.29% |
| 5 | Communication Services | 9.4% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
KW
901
DELISTED
Kennedy-Wilson Holdings
KW
| $32.3M | 0.01% |
1,447,152
+294,747
| +26% | +$6.6M |
|
|
SRCL
902
DELISTED
Stericycle Inc
SRCL
| $32.3M | 0.01% |
505,415
-19,263
| -4% | -$1.14M |
|
|
LOGM
903
DELISTED
LogMein, Inc.
LOGM
| $32.2M | 0.01% |
375,421
-3,676
| -1% | -$273K |
|
|
KYNB
904
Kyntra Bio
KYNB
$29.4M
| $32.2M | 0.01% |
29,986
+9,506
| +46% | +$9.7M |
|
905
Progress Software
PRGS
$1.76B
| $32.1M | 0.01% |
773,582
+32,375
| +4% | +$1.32M |
|
906
NCR Voyix
VYX
$1.14B
| $32.1M | 0.01% |
1,486,527
-425,931
| -22% | -$8.29M |
|
|
AMED
907
DELISTED
Amedisys
AMED
| $32M | 0.01% |
191,486
-63,634
| -25% | -$9.46M |
|
908
Pebblebrook Hotel Trust
PEB
$2.05B
| $32M | 0.01% |
1,192,194
-373,412
| -24% | -$9.84M |
|
909
IDEX
IEX
$17.3B
| $31.9M | 0.01% |
185,655
-63,244
| -25% | -$10.2M |
|
910
XPO
XPO
$23.7B
| $31.9M | 0.01% |
1,157,301
+173,377
| +18% | +$4.76M |
|
911
NeoGenomics
NEO
$2.13B
| $31.9M | 0.01% |
1,090,324
-47,437
| -4% | -$1.13M |
|
912
Selective Insurance
SIGI
$5.73B
| $31.9M | 0.01% |
488,647
+149,520
| +44% | +$10.3M |
|
913
AGCO
AGCO
$7.2B
| $31.8M | 0.01% |
411,467
-61,807
| -13% | -$4.74M |
|
914
Landstar System
LSTR
$6.21B
| $31.8M | 0.01% |
279,092
+37,417
| +15% | +$4.22M |
|
915
PTC Therapeutics
PTCT
$6.12B
| $31.7M | 0.01% |
660,091
+365,512
| +124% | +$15.5M |
|
916
Murphy USA
MUSA
$9.61B
| $31.7M | 0.01% |
270,721
-33,134
| -11% | -$3.57M |
|
917
Brown-Forman Class B
BF.B
$13.1B
| $31.6M | 0.01% |
468,174
-102,924
| -18% | -$6.68M |
|
918
Trex
TREX
$5.01B
| $31.5M | 0.01% |
701,948
-23,916
| -3% | -$1.05M |
|
919
Neogen
NEOG
$2.5B
| $31.4M | 0.01% |
963,138
-49,780
| -5% | -$1.64M |
|
920
Lear
LEA
$8.18B
| $31.3M | 0.01% |
227,940
-6,518
| -3% | -$808K |
|
921
Sanofi
SNY
$104B
| $31.2M | 0.01% |
620,583
-49,707
| -7% | -$2.33M |
|
922
Plains GP Holdings
PAGP
$4.9B
| $31M | 0.01% |
1,634,324
-555,239
| -25% | -$10.4M |
|
923
DaVita
DVA
$11.7B
| $30.7M | 0.01% |
408,923
+107,342
| +36% | +$7.12M |
|
924
Primerica
PRI
$9.89B
| $30.6M | 0.01% |
234,393
-52,429
| -18% | -$6.77M |
|
925
FIVE9
FIVN
$2.54B
| $30.6M | 0.01% |
466,361
-305,368
| -40% | -$18.7M |
|
Similar funds
VFT
Nuveen's Q4 2019 Portfolio in Review
As of Q4 2019, Nuveen held 3,331 positions worth $264B, up 6.7% from $247B the previous quarter. Its ten largest holdings account for 19% of the portfolio.
Nuveen's Q4 2019 filing shows 118 new, 1,090 increased, 1,840 reduced and 95 closed positions. Its largest new stake was iShares iBoxx $ Investment Grade Corporate Bond ETF: 8,077,161 shares worth $1.03B. The largest sale was Cisco, an estimated $474M.
By sector, the portfolio is most concentrated in Technology at 21% of assets, up from 20% a quarter earlier, followed by Financials and Healthcare.
- Nuveen's largest Q4 2019 buy was iShares iBoxx $ Investment Grade Corporate Bond ETF: 8,077,161 shares worth $1.03B.
- Nuveen added most to Bristol-Myers Squibb in Q4 2019, an estimated $649M increase.
- Nuveen's biggest Q4 2019 reduction was Cisco, cutting an estimated $474M.
- Nuveen fully exited Celgene Corp in Q4 2019, selling an estimated $421M.
- Nuveen's ten largest holdings make up 19% of its $264B portfolio in Q4 2019.
- Nuveen opened 118 new positions and closed 95 in Q4 2019.
- Nuveen's portfolio value rose 6.7% quarter-over-quarter to $264B.
Based on Nuveen's 13F filing for Q4 2019, filed 14 Feb 2020.